Severe Atopic Dermatitis Market: Innovative Therapies, Clinical Competition, and Future Opportunities

Severe atopic dermatitis is a persistent inflammatory skin condition characterized by intense itching, dryness, redness, irritation, and recurrent lesions that can significantly interfere with daily life. Its development is associated with immune-system dysfunction, genetic factors, and environmental influences. According to DelveInsight, the atopic dermatitis market represents a substantial therapeutic opportunity across the United States, EU4, the United Kingdom, and Japan. In 2023, the seven major markets accounted for an estimated 72.7 million prevalent atopic dermatitis cases, demonstrating the considerable disease burden and ongoing requirement for effective treatment options.

Severe Atopic Dermatitis Market Burden and Patient Population

Moderate-to-severe atopic dermatitis remains an important area of clinical and commercial interest because patients with widespread disease or insufficient response to topical treatment may require systemic intervention. DelveInsight estimated around 3.34 million diagnosed severe atopic dermatitis cases across the 7MM in 2023, compared with approximately 19.29 million moderate cases and 30.90 million mild cases. The United States accounted for a substantial proportion of this burden, with an estimated 32.76 million prevalent cases and nearly 9.93 million moderate-to-severe cases during the same year.

The commercial landscape has also evolved alongside the introduction of targeted biologics and oral therapies. In 2023, the moderate-to-severe atopic dermatitis market across the 7MM was estimated at approximately USD 10.4 billion, while the United States contributed nearly USD 7.1 billion. These market figures highlight the growing importance of systemic therapies and the continuing demand for treatments that can provide sustained control of severe disease.

Severe Atopic Dermatitis Treatment Landscape

Treatment selection for atopic dermatitis is influenced by factors such as disease severity, patient age, extent of skin involvement, symptom intensity, and previous treatment outcomes. Conventional management may include moisturizers, topical corticosteroids, and topical calcineurin inhibitors. Patients with more extensive or treatment-resistant disease may require phototherapy or systemic medications.

The therapeutic landscape changed considerably after the introduction of DUPIXENT (dupilumab), which received approval for moderate-to-severe atopic dermatitis in 2017. Its indications were subsequently expanded to include additional pediatric and adolescent populations. The arrival of newer biologics and oral targeted treatments has further diversified treatment options for patients who continue to experience inadequate disease control.

Severe Atopic Dermatitis and the Rise of IL-13 Inhibitors

IL-13 has emerged as a significant therapeutic target because of its involvement in type 2 inflammation associated with atopic dermatitis. EBGLYSS (lebrikizumab) is a monoclonal antibody designed to selectively inhibit IL-13 signaling and has become an important therapy within the treatment landscape.

EBGLYSS received U.S. FDA approval in September 2024 for adults and pediatric patients aged 12 years and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis that is not adequately controlled by topical prescription therapies. Regulatory approvals in the European Union and Japan have further expanded its presence across major pharmaceutical markets.

Severe Atopic Dermatitis Clinical Development of EBGLYSS and ADBRY

Increasing competition among targeted therapies has generated considerable interest in comparative clinical development. The ebglyss vs adbry in ad clinical trials discussion focuses on two biologics that target the IL-13 pathway. EBGLYSS is designed to inhibit IL-13, while ADBRY, marketed as ADTRALZA in markets outside the United States, is another IL-13-directed biologic developed for patients with moderate-to-severe atopic dermatitis.

ADBRY has received regulatory approvals in several countries for eligible patients with moderate-to-severe disease. In the United States, it received FDA approval in December 2021 for adults whose condition was inadequately controlled with topical prescription therapies or when such treatments were not advisable. Its broader international availability has contributed to the expanding competitive environment for targeted atopic dermatitis therapies.

Severe Atopic Dermatitis Evidence From Atopic Eczema Clinical Trials

With multiple therapies targeting similar inflammatory mechanisms, clinical evidence plays an important role in understanding treatment characteristics. Interest in ebglyss vs adbry in atopic eczema clinical trials includes comparisons involving efficacy outcomes, safety profiles, treatment schedules, and patient responses.

The competitive environment extends beyond IL-13 inhibitors. Oral JAK inhibitors such as RINVOQ and CIBINQO offer alternative systemic approaches, while DUPIXENT remains an established biologic option. Other therapies and investigational programs are targeting IL-31, topical inflammatory pathways, and several additional immune mechanisms, creating a broad and increasingly diversified therapeutic landscape.

Severe Atopic Dermatitis Pipeline and Emerging Therapies

Drug development continues to investigate multiple biological pathways associated with severe atopic dermatitis. According to DelveInsight, emerging candidates are exploring targets such as IL-4, IL-13, IL-22, IL-31, TSLP, and the OX40-OX40L signaling pathway. Companies participating in the development landscape include Kyowa Kirin, Amgen, Sanofi, UNION Therapeutics, Aclaris Therapeutics, Connect Biopharma, Apogee Therapeutics, and other pharmaceutical and biotechnology organizations.

These emerging approaches could introduce additional treatment choices for patients who experience an inadequate response to existing therapies. Development programs are also increasingly examining treatment durability, safety, administration frequency, adherence, and convenience alongside traditional efficacy measurements.

Severe Atopic Dermatitis Competition Between EBGLYSS and ADBRY

The ebglyss vs adbry in atopic dermatitis clinical trials comparison has become relevant within the growing IL-13 inhibitor segment. Clinical trial differences can involve study populations, treatment duration, dosing regimens, efficacy endpoints, trial designs, and reported safety outcomes. These factors contribute to how individual therapies are evaluated within the broader treatment environment.

Treatment convenience is another consideration within the evolving market. Pharmaceutical developers are investigating regimens that may reduce administration frequency while maintaining disease control. Such innovations could become increasingly relevant to treatment adherence and patient experience as the severe atopic dermatitis therapeutic landscape develops.

Severe Atopic Dermatitis Treatment Market Growth Opportunities

The atopic dermatitis treatment market continues to attract pharmaceutical investment because of the large patient population, persistent unmet treatment needs, and expanding range of targeted therapies. Pediatric treatment is another important development area, particularly as younger patients may require therapies with appropriate long-term safety and effective disease management.

DelveInsight's analysis evaluates epidemiological trends and market dynamics across the United States, EU4, the United Kingdom, and Japan through 2034. The assessment includes patient populations, treatment patterns, market size, individual therapy performance, emerging drugs, unmet needs, and competitive developments, offering insight into how the treatment environment may evolve.

Conclusion

Severe atopic dermatitis is experiencing continued therapeutic advancement as biologics, JAK inhibitors, topical medicines, and pipeline candidates expand available treatment approaches. IL-13-directed therapies have become an important part of this changing environment, while emerging programs are exploring additional immune pathways and potentially more convenient treatment strategies. The substantial patient population and continuing clinical innovation across major pharmaceutical markets are expected to sustain interest in severe atopic dermatitis research, drug development, and market opportunities.

Latest Reports by DelveInsight:

intracardiac echocardiography market | myopia progression market | osteomyelitis market | pulse oximeters market | respiratory inhalers market | sleep tech devices market | spinal trauma devices market | walking impairment in multiple sclerosis market | wolman disease market | car t cell therapy market | acrocallosal syndrome market | Attention Deficit Hyperactivity Disorder Market | duchenne muscular dystrophy market | parkinson disease market | radial artery compression device market | optical coherence tomography devices market | amyotrophic lateral sclerosis market | continuous renal replacement therapy machines market | diabetic nephropathy market | post operative pain market

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com